New Johnson & Johnson data shows second shot boosts antibodies and protection against Covid-19

Your body produces antibodies after an infection or vaccine, but these slowly decline over time. New Johnson & Johnson data sheds light on the duration of protection and the need for booster

On Sept. 22, 2021, Johnson & Johnson released information showing that a booster shot produced stronger immunity than the single dose. AP Photo/David Zalubowski

  1. How effective is one dose of the Johnson & Johnson vaccine?

Early clinical trial data released in January 2021 showed that four weeks after the first dose, the Johnson & Johnson single-shot vaccine was 66.3% effective at preventing COVID-19 infection. The initial studies also showed that it was 85% effective at preventing severe or critical disease.

But the original clinical trials and most subsequent studies were done before the delta variant became responsible for almost all of the COVID-19 cases in the U.S. Early studies suggest that although COVID-19 vaccines are still effective against this variant, in general their efficacy is lower compared to protection against the original strain.

On Sept. 21, 2021, Johnson and Johnson announced the results of a large, real-world Phase 3 clinical trail of its COVID-19 vaccine. This study collected data from March 1, 2020, through July 31, 2021, and found that the effectiveness of the vaccine did not diminish over the duration of the study, even after the delta variant became dominant in the U.S. The one-dose vaccine was 79% protective against COVID-19 infections and 81% protective for COVID-19-related hospitalizations. This indicates that a single Johnson & Johnson shot performs well, even in the presence of the delta and other variants.

  1. Why might someone need a booster?

The amount of neutralizing antibodies in a person – antibodies that defend a cell from the coronavirus – is an accurate measure of protection within the first

several months after vaccination. Studies show that individuals who received a Johnson & Johnson or an mRNA vaccine continue to produce some level of anti-bodies for at least six months after vaccination. However, neutralizing antibody

levels generally start to wane over time and some evidence suggests that immunity provided by the Pfizer mRNA vaccine does the same.

This may sound bad, but it isn’t clear that lower antibody levels correlate with an increased risk of severe infection. The immune system’s long-term surveillance is done by “memory” immune cells that will prevent or reduce disease severity if a person is exposed to the coronavirus at a later time.

Therefore scientists have been collec-ting real-world data from vaccinated

people to determine when they may become vulnerable to infection again with and without a booster shot.

  1. How effective is a Johnson & Johnson booster shot?

In addition to the results of the single–shot study, on Sept 21, 2021, Johnson & Johnson also released data about boos-ter shots. The trial gave people a second dose of the Johnson & Johnson vaccine either two or six months after the first dose. In both cases, it increased people’s defense against COVID–19.

When given two months after the first dose, protection against moderate to severe disease increased from 85% to 94% and the amount of neutralizing antibodies increased four-fold. If the booster was administered six months after the first shot, antibody levels increased 12-fold, when measured four weeks after the booster was given.

These findings suggest that although a single dose of the Johnson & Johnson

vaccine provides strong, durable protection, people may still benefit from a booster because it improves the vaccine’s efficacy.

One important question is whether someone who received the Johnson & Johnson shot should get a second Johnson & Johnson dose or mix and match – get a second dose of a different vaccine. As of late September, the FDA seems more likely to approve a second dose of the Johnson & Johnson vaccine because there isn’t much data yet about a mix-and-match strategy.

  1. What about the side effects?

The vast majority of vaccines – inclu-ding the Johnson & Johnson and mRNA COVID-19 vaccines – produce common side effects, such as pain at the injection site, headache, fatigue, muscle and joint pain, chills and fever.

The recent study did not monitor side effects from the booster in detail, but according to Johnson & Johnson, the safety of the vaccine remained consistent and was generally well-tolerated when

administered as a booster. Overall, researchers have repeatedly found that despite some rare complications, the

benefits of the Johnson & Johnson vaccine far outweigh the risks.

A recent CDC study showed that unvaccinated people are almost five times more likely to be infected by the coro-navirus and 29 times more likely to be hospitalized with COVID-19 compared to fully vaccinated individuals. Therefore, all the evidence suggests that the millions of Americans who are able to get vaccinated but are choosing not to are putting themselves – and others – at serious risk.

  1. When might a booster be autho-rized?

On Sept, 22, 2021, the FDA approved booster shots for people who received the Pfizer vaccine and are 65 years of age and older, at risk of severe COVID-19 illness or whose occupations put them at greater risk of exposure. Booster shots of the Johnson & Johnson or Moderna vaccines are not yet approved, but on Sept. 19, Dr. Anthony Fauci said that the FDA could review booster data for the Moderna and Johnson & Johnson vaccines within a few weeks.

Maureen Ferran
Associate Professor of Biology,
Rochester Institute of Technology


* Published in print edition on 5 October 2021

An Appeal

Dear Reader

65 years ago Mauritius Times was founded with a resolve to fight for justice and fairness and the advancement of the public good. It has never deviated from this principle no matter how daunting the challenges and how costly the price it has had to pay at different times of our history.

With print journalism struggling to keep afloat due to falling advertising revenues and the wide availability of free sources of information, it is crucially important for the Mauritius Times to survive and prosper. We can only continue doing it with the support of our readers.

The best way you can support our efforts is to take a subscription or by making a recurring donation through a Standing Order to our non-profit Foundation.
Thank you.

Add a Comment

Your email address will not be published.